Matrixx Initiatives ups its buyout offer for ProPhase Labs (PRPH) by 14% to $1.60/share in cash from its earlier offer of $1.40 that PRPH had rejected. Matrixx is a private firm that makes Zicam cold medicine, a competitor to PRPH's Cold-Eeze product line.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs